^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ARID1A mutation

    i
    Other names: ARID1A, AT-Rich Interaction Domain 1A, SWI/SNF-Related, Matrix-Associated, Actin-Dependent Regulator Of Chromatin Subfamily F Member 1, AT-Rich Interactive Domain-Containing Protein 1A, AT Rich Interactive Domain 1A (SWI-Like), ARID Domain-Containing Protein 1A, SWI/SNF Complex Protein P270, BRG1-Associated Factor 250a, SWI-Like Protein, Osa Homolog 1, SMARCF1, C1orf4, BAF250, HOSA1, OSA1, AT Rich Interactive Domain 1A (SWI- Like), Chromatin Remodeling Factor P250, BRG1-Associated Factor 250, OS
    Entrez ID:
    8289
    Related biomarkers:
    Mutation
    CNA
    Others
    3d
    Clinical and Molecular Characterization of Clear Cell Adenocarcinoma of the Urinary Tract: A Multi-Institutional Study. (PubMed, Am J Surg Pathol)
    However, there was no statistical significance in the progression-free survival between cases with epithelial and mesenchymal phenotypes. CCA-UT are aggressive tumors with a heterogeneous molecular profile, underscoring the role of molecular analysis in identifying potential therapeutic options for the treatment of this pernicious tumor.
    Clinical • Journal • Tumor mutational burden • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • ATM (ATM serine/threonine kinase) • ARID1A (AT-rich interaction domain 1A) • NF1 (Neurofibromin 1) • KMT2C (Lysine Methyltransferase 2C) • ATRX (ATRX Chromatin Remodeler) • BRCA (Breast cancer early onset) • ARID1B (AT-Rich Interaction Domain 1B)
    |
    ATM mutation • ARID1A mutation • BRCA mutation
    8d
    ARID1A Deficiency in Diffuse-Type Gastric Cancer Promotes a Pyrimidine Metabolic Vulnerability. (PubMed, Mol Cancer Res)
    Implications: This work uncovers a metabolic vulnerability in ARID1A-deficient gastric cancer caused by SLC28A3 loss. It provides a compelling rationale for repurposing Gemcitabine as a targeted therapy for this intractable malignancy.
    Journal
    |
    ARID1A (AT-rich interaction domain 1A) • SLC28A3 (Solute Carrier Family 28 Member 3)
    |
    ARID1A mutation
    |
    gemcitabine
    8d
    Genomic Landscape of Poorly Differentiated Gastric Carcinoma: An AACR GENIE® Project. (PubMed, Life (Basel))
    Metastatic enrichment of CDH1 and MLH1 supports their roles in invasion and therapeutic resistance. Together, these findings highlight candidate biomarkers and actionable pathways warranting validation in larger, multi-omic cohorts to refine precision treatment strategies for this aggressive gastric cancer subtype.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • ARID1A (AT-rich interaction domain 1A) • CCNE1 (Cyclin E1) • MLH1 (MutL homolog 1) • KMT2D (Lysine Methyltransferase 2D) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • KMT2C (Lysine Methyltransferase 2C) • CDH1 (Cadherin 1) • FAT1 (FAT atypical cadherin 1) • POLD1 (DNA Polymerase Delta 1)
    |
    TP53 mutation • ARID1A mutation • FGFR2 mutation
    8d
    Identification of the Carcinogenic Process from Lobular Endocervical Glandular Hyperplasia to Gastric-Type Adenocarcinoma of the Uterine Cervix via Whole-Exome Sequencing. (PubMed, Cancers (Basel))
    In contrast, SMAD4 and SMAD2 showed frequent loss-of-function-type alterations in GAS, including copy-number loss, but were not detected in LEGH. These findings provide insights into the genomic landscapes of LEGH and GAS and suggest potential molecular markers for this transition, which may inform future diagnostic and therapeutic research.
    Journal
    |
    STK11 (Serine/threonine kinase 11) • ARID1A (AT-rich interaction domain 1A) • SMAD4 (SMAD family member 4) • PTPRT (Protein tyrosine phosphatase receptor type T) • PTPRF (Receptor-type tyrosine-protein phosphatase F) • SMAD2 (SMAD Family Member 2)
    |
    ARID1A mutation • STK11 mutation
    9d
    Genomic and immunological differences in endometrial cancer: a comparative study between young and old Asian patients. (PubMed, Front Immunol)
    These age-specific molecular subtypes correlated with significant survival differences. Our study identifies conserved age-specific molecular subtypes of EC and reveals population-specific genomic features, underscoring the need for age-tailored and ethnicity-aware therapeutic strategies.
    Journal • Tumor mutational burden
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • MSH6 (MutS homolog 6) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1)
    |
    TP53 mutation • KRAS mutation • PIK3CA mutation • PTEN mutation • ARID1A mutation • FGFR2 mutation • MET mutation
    16d
    Real-World Genomic Landscape of Korean Gastric Cancer: Integrating Biomarker Associations and Clinical Outcomes in Metastatic Gastric Cancer. (PubMed, JCO Precis Oncol)
    Our findings provide a comprehensive genomic landscape of Korean gastric cancer and underscore the clinical relevance of integrating genomic and established biomarkers to advance precision oncology.
    Clinical data • Journal • Real-world evidence • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • FGFR2 (Fibroblast growth factor receptor 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • CCNE1 (Cyclin E1) • BCOR (BCL6 Corepressor)
    |
    TP53 mutation • TMB-H • HER-2 amplification • PIK3CA mutation • ARID1A mutation • FGFR2 mutation • TMB-L • EGFR positive
    |
    Opdivo (nivolumab)
    16d
    Integrative multi-omics defines melanoma drug response networks and ARID1A-dependent resistance mechanisms. (PubMed, Mol Syst Biol)
    ARID1A-KO also reduced HLA-related protein expression and enhanced extracellular matrix components, potentially limiting immune infiltration and immunotherapy efficacy. Our multi-omics analysis revealed PRKD1, JUN, and NCK1 as key resistance nodes, offering potential targets for therapeutic strategies to counter resistance in melanoma.
    Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • ARID1A (AT-rich interaction domain 1A) • MAPK1 (Mitogen-activated protein kinase 1) • PRKD1 (Protein Kinase D1)
    |
    BRAF V600E • BRAF V600 • ARID1A mutation
    22d
    Efficacy of the ATR inhibitor ceralasertib in patients with ARID1A-deficient gynecologic and other solid tumor malignancies. (PubMed, Clin Cancer Res)
    Ceralasertib monotherapy demonstrated promising anti-tumor activity in ARID1A-deficient gynecologic malignancies. Tumor molecular and immune correlates may inform the further development of ATR inhibitors in this patient population.
    Journal
    |
    ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    |
    ceralasertib (AZD6738)
    27d
    Primary peritoneal clear cell carcinoma with metastasis mimicking ovarian carcinoma: a case report and literature review. (PubMed, J Ovarian Res)
    This case highlights the diagnostic challenges of PPCCC and offers valuable insights into the clinical and pathological spectrum of this underrecognized malignancy.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ARID1A (AT-rich interaction domain 1A) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PAX8 (Paired box 8)
    |
    PIK3CA mutation • ARID1A mutation
    29d
    Interpretable deep learning model of circulating genomics for quantitative survival prediction in advanced non-small cell lung cancer. (PubMed, Clin Transl Oncol)
    The interpretable DeepSurv model, integrating multimodal features, enables quantitative survival prediction and risk stratification in advanced NSCLC, facilitating personalized decision-making.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • STK11 (Serine/threonine kinase 11) • ARID1A (AT-rich interaction domain 1A)
    |
    TP53 mutation • EGFR mutation • PIK3CA mutation • ARID1A mutation • STK11 mutation • MET mutation
    |
    MSK-ACCESS
    1m
    ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu (clinicaltrials.gov)
    P1, N=34, Not yet recruiting, University of California, Irvine | Initiation date: Nov 2025 --> Apr 2026
    Trial initiation date • Checkpoint inhibition • IO biomarker
    |
    ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    1m
    Evaluate the Safety and Clinical Activity of HH2853 (clinicaltrials.gov)
    P1/2, N=254, Recruiting, Haihe Biopharma Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    ARID1A (AT-rich interaction domain 1A) • BAP1 (BRCA1 Associated Protein 1)
    |
    ARID1A mutation • EZH2 mutation
    |
    HH2853